

Search search phrase...

Login With Facebook

Login With LinkedIn

Register for up to date access

Log In

	Home	Conferences	Calendar	Information Center	Media	Editor's Blog	Contact Us	Urologic Catheters	UroToday International Journal	My Alert Subscriptions
You are here: Home GU Cancers Kidney Cancer The role of metastasectomy in renal cell carcinoma in the era of targeted therapy - Abstract										

The role of metastasectomy in renal cell carcinoma in the era of targeted therapy - Abstract

Published on 03-26-2013

Despite contemporary innovations in systemic therapy and surgical treatment, renal cell carcinoma (RCC) remains the most lethal urologic malignancy.

Still, around 20 % of patients with RCC present with metastases at diagnosis, and 40-50 % of those with localized advanced disease will ultimately progress to metastatic disease. Although the new, targeted therapy paradigms have changed the treatment of patients with advanced RCC and offer prolonged survival, cure is extremely uncommon in the absence of surgical resections. In this paper, the current role of metastasectomy is reviewed. Searches were carried out in the PubMed database and the Cochrane Library of Controlled Clinical Trials. While there is no randomized study available, recent large observational studies have better defined the prognosis of patients with metastatic RCC with or without metastasectomy. In multivariate analysis, independent predictive factors included male gender, disease-free interval > 1 year, single metastatic site and complete metastasectomy. Other reports from selected patient materials show 29-31 % 5-year overall survival rates. In patients with recurrent disease after resection of a lung metastasis, 60 % were able to undergo a subsequent resection, compared with 25 % with recurrent bone metastasis. Also, metastasectomy after initial systemic therapy gave partial or complete response in a majority of patients. In these patients, the median survival was 4.7 years and 21 % remained free of disease at last follow-up. Patients with metastatic renal cell carcinoma should be considered for multimodal therapy, including surgery of metastatic lesions. A proportion of patients will achieve long-term survival with aggressive surgical resection.

Written by:

Ljungberg B. Are you the author?

Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.

Borje.Ljungberg@urologi.umu.se

Reference: Curr Urol Rep. 2013 Feb;14(1):19-25. doi: 10.1007/s11934-012-0293-6

PubMed Abstract

PMID: 23212738

UroToday.com Renal Cancer Section



Tags:

Comments (0) Search

Only registered users can write comments!

RENAL CANCER

Imaging Treatment Grading and Staging Pathology Guidelines Incidence - Etiology Epidemiology Clinical Presentation Clinical Staging Prognosis Clinical Follow Up

DISEASE TOPICS

Prostate Bladder Kidney **GU Cancers Urologic Catheters** Erectile Dysfunction Peyronie's Disease Men's Health Women's Health Investigative Urology Infections Stone Disease Endourology Trauma/Reconstruction Pediatric Urology Urology Training/Practice Clinical Trials

3/27/2013 9:26 AM 1 of 2

The role of metastasectomy in renal cell carcinoma in the era of targeted t... http://www.urotoday.com/Renal-Cancer/the-role-of-metastasectomy-in-re...

Topics on Urology Health, Urinary Leakage, Treating Prostate Cancer, Prostate Cancer Diagnosis, Urology News, Symptoms For Bladder Infection In Men

Copyright © 2002 - 2013 Digital Science Press, Inc.

website design firm : Web-JIVE LLC

2 of 2